

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (cancelled)
2. (currently amended) The implant of Claim 4~~12~~, wherein the degradation characteristic $D_2(x)$ of the coating is provided by varying its morphological structure, material modification of the material, or adapting a layer thickness of the coating.
3. (currently amended) The implant of Claim 4~~12~~, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the pathophysiological conditions to be expected in application.
4. (currently amended) The implant of Claim 4~~12~~, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the rheological conditions to be expected in application.
5. (previously presented) The implant of Claim 2, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the pathophysiological conditions to be expected in application.
6. (previously presented) The implant of Claim 2, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the rheological conditions to be expected in application.

7. (currently amended) The implant of Claim 412, wherein the metallic alloy includes at least one material selected from the group consisting of magnesium, iron, tungsten and WE43 (which is composed of yttrium 3.7-4.3%, rare earths 2.4-4.4%, zirconium 0.4% min, and the balance magnesium).
8. (currently amended) The implant of Claim 412, wherein the coating includes an alloy comprising at least one material selected from the group consisting of magnesium, iron, tungsten and WE43 (which is composed of yttrium 3.7-4.3%, rare earths 2.4-4.4%, zirconium 0.4% min, and the balance magnesium).
9. (currently amended) The implant of Claim 412, wherein the coating comprises at least one material selected from the group consisting of cellulose, collagen, albumin, casein, polysaccharides (PSAC), polylactide (PLA), poly-L-lactide (PLLA), polyglycol (PGA), poly-D,L-lactide-co-glycolide (PDLLA/PGA), polyhydroxy butyric acid (PHB), polyhydroxy valeric acid (PHV), polyalkylcarbonates, polyorthoester, polyethylene terephthalate (PET), polymalic acid (PML), polyanhydrides, polyphosphazenes, polyamino acids and their copolymers, hyaluronic acid, and derivatives, blends and copolymers of the foregoing.
10. (currently amended) The implant of Claim 412, wherein the coating comprises at least two biodegradable polymeric or metallic materials, wherein each material is disposed on the main body at either different locations or as multilayer systems at specific distinct locations on the main body.
11. (currently amended) The implant of Claim 412, wherein the surface of the at least one coating is porous.

12. (new) An endovascular implant, comprising:
 - a) a tubular main body having a longitudinal axis and open first and second ends and comprising at least one biodegradable material made of a metallic alloy, the main body having a location-dependent first degradation characteristic $D_1(x)$ in vivo; and
 - b) a first coating which covers a portion of the main body at a first location, the first coating comprising at least one biodegradable material, the first coating having a location-dependent second degradation characteristic $D_2(x)$ in vivo,
 - c) a second coating which covers a portion of the main body at a second location, the second coating comprising at least one biodegradable material, the coating having a location-dependent second degradation characteristic $D_2(x)$ in vivo, and
 - d) a third coating which covers a portion of the main body and is disposed at a third location between the first and second locations, the third coating comprising at least one biodegradable material, the third coating having a location-dependent third degradation characteristic $D_2(x)$ in vivo,
wherein the first and second coatings degrade at a different rate than the third coating.
13. (new) The implant of Claim 12, wherein the first and second coatings degrade at a faster rate than the third coating.
14. (new) The implant of Claim 12, wherein the stent degrades at a non-progressive rate from the first end to the second end of the tubular main body longitudinal axis.
15. (new) The implant of Claim 12, wherein the third coating thickness is different than the first and second coating thicknesses.
16. (new) The implant of Claim 12, wherein at least one of the first and second coatings comprises two different materials.

17. (new) The implant of Claim 12, wherein at least one of the first and second coatings comprises at least two layers, each layer being formed from a different material.
18. (new) The implant of Claim 12, wherein the first and second coatings are crosslinked to a different degree than the third coating.
19. (new) The implant of Claim 12, wherein the first and second coatings are proximate to the first and second ends, respectively.